Prostate cancer is the most commonly diagnosed malignancy in men and the second
leading cause of cancer-related deaths in Western civilization. Although localized prostate …

Evolutionary pressure has selected antibodies as key immune molecules acting against
foreign pathogens. The development of monoclonal antibody technology has allowed their …

The adoptive transfer of T cells redirected to tumor-associated antigens via transgenic
expression of chimeric antigen receptors (CARs) has produced tumor responses, even in …

Noninvasive molecular imaging approaches include nuclear, optical, magnetic resonance
imaging, computed tomography, ultrasound, and photoacoustic imaging, which require …

Despite advances in the understanding of its molecular pathophysiology, pancreatic cancer
remains largely incurable, highlighting the need for novel therapies. We developed a …

Identification of cancer cell–surface biomarkers and advances in antibody engineering have
led to a sharp increase in the development of therapeutic antibodies. These same advances …

We conducted a phase I dose-escalation study with 89Zr-desferrioxamine-IAB2M (89Zr-
IAB2M), an anti–prostate-specific membrane antigen minibody, in patients with metastatic …

Antibodies have long been recognised as potent vectors for carrying diagnostic medical
radionuclides, contrast agents and optical probes to diseased tissue for imaging. The area of …

Highlights•36 out of 39 approved therapeutic antibodies are native full-length IgG.•Antibody
engineering may increase potency and improve safety of native antibodies.•Next generation …

Antibody technology has transformed drug development, providing robust approaches to
producing highly targeted and active therapeutics that can routinely be advanced through …